Figure 3.

Incidence rates, NNT and treatment effect by TRS‐HF_DM category for (A) CV death, (B) all‐cause mortality, (C) HHF and (D) CV death† or HHF for empagliflozin versus placebo in patients without HF at baseline. CI, confidence interval; CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; HR, hazard ratio; NNT, number needed to treat; TRS‐HF_DM, Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes. †Excluding fatal stroke. 95% CI shown in brackets: HR (95% CI)